DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: FLOVENT HFA

Summary for Tradename: FLOVENT HFA

Patents:18
Applicants:1
NDAs:1
Suppliers: see list4
2013 Sales:$1,050,009,000
drug
patent expirations by year for
 FLOVENT HFA

Pharmacology for Tradename: FLOVENT HFA

Clinical Trials for: FLOVENT HFA

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiFormâ„¢) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
Status: Completed Condition: Asthma

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma
Status: Completed Condition: Asthma

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
Status: Completed Condition: Asthma

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
Status: Recruiting Condition: Persistent Asthma

Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays
Status: Completed Condition: Allergic Rhinitis

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
Status: Completed Condition: Asthma

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
Status: Completed Condition: Asthma

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
Status: Completed Condition: Asthma

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma
Status: Not yet recruiting Condition: Asthma

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Status: Recruiting Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes5,658,549*PED<disabled>Y<disabled>
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes5,674,472*PED<disabled>Y<disabled>
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes6,161,724*PED<disabled>Y<disabled>
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433May 14, 2004RXYes6,170,717*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc